Fiche centre
Stanford University
Palo Alto — United States
Essais liés25clinical trials
VillePalo Altolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04770220
Essais cliniques associés
25| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NRTX-1001 | Épilepsie | Phase 3 | NCT05135091 | Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) | RECRUITING |
| Obecabtagene autoleucel (obe-cel) | SEP | Phase 1 | NCT07139743 | BOBCAT — Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | RECRUITING |
| Ataluren | Myopathies | Phase 3 | NCT01247207 | Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) | TERMINATED |
| AOC 1001 | Myopathies | Phase 1/2 | NCT05027269 | MARINA — Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients | COMPLETED |
| Sirolimus | Épilepsie | Phase 2 | NCT05104983 | TSC-STEPS — Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | ACTIVE_NOT_RECRUITING |
| Experimental: ALZ-801 | Alzheimer | Phase 3 | NCT04770220 | APOLLOE4 — An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects | COMPLETED |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1 | NCT07443137 | CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | NOT_YET_RECRUITING |
| AOC 1001 | Myopathies | Phase 2 | NCT05479981 | MARINA-OLE — Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients | COMPLETED |
| ONO-2020 | Alzheimer | Phase 2 | NCT06881836 | A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Phenotype, Genotype & Biomarkers in ALS and Related Disorders | Sclérose latérale amyotrophique | À vérifier | NCT02327845 | Phenotype, Genotype & Biomarkers in ALS and Related Disorders | ACTIVE_NOT_RECRUITING |
| CAPTURE-ALS — Clinical Procedures to Support Research in ALS | Sclérose latérale amyotrophique | À vérifier | NCT03489278 | CAPTURE-ALS — Clinical Procedures to Support Research in ALS | RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| delandistrogene moxeparvovec | Myopathies | Phase 1 | NCT04626674 | ENDEAVOR — A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | RECRUITING |
| AOC 1020 | Myopathies | Phase 2 | NCT06547216 | FORTITUDE-OLE — Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | ACTIVE_NOT_RECRUITING |
| AOC 1020 | Myopathies | Phase 1/2 | NCT05747924 | FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED |
| AAV9-hSyn1-miGRIK2 | Épilepsie | Phase 1/2 | NCT06063850 | GenTLE — AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Vamorolone | Myopathies | À vérifier | NCT06564974 | DMD-001 SUMMIT — Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT | RECRUITING |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| silevertinib in combination with temozolomide | Cancer | Phase 2 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | RECRUITING |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| extended release metformin | Alzheimer | Phase 2/3 | NCT04098666 | MAP — Metformin in Alzheimer's Dementia Prevention | ACTIVE_NOT_RECRUITING |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |